Contineum Therapeutics (CTNM): Net loss widened to $48.3M for nine months ended Sept 30, 2026
Q3 2026 10-Q: nine-month net loss $48.3M vs $44.8M a year ago; operating cash burn $38.8M; ATM stock sales raised $19.4M.
What this filing says
Contineum Therapeutics reported a nine-month net loss of $48.3 million for the period ended September 30, 2026, up from $44.8 million a year earlier. Operating cash burn was $38.8 million, and the company raised $19.4 million from its at-the-market stock sales, which can add shares outstanding and dilute existing holders. The filing also warns that FDA staffing cuts and government shutdowns could slow reviews of its drug candidates.
Key figures
- Nine-month net loss
- $48.3 million
- Prior-year nine-month net loss
- $44.8 million
- Net cash used in operations
- $38.8 million
- At-the-market stock proceeds
- $19.4 million
Positive for shareholders
- Non-cash charges of $13.8 million partly offset the operating cash outflow.
- Breakthrough and orphan drug designations, if granted, may speed development for its candidates.
Negative for shareholders
- The net loss grew compared with the same period last year.
- Operating cash use rose only modestly, but the company still depends on raising capital through stock sales.
- FDA staffing cuts and government shutdowns could delay reviews of its drug candidates.
- Designations such as breakthrough therapy do not assure approval or a faster process.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- At-the-market offering:
- A way for a company to sell new shares gradually into the open market at current prices through a broker.
- Dilutive securities:
- Options, warrants and similar rights that could create new shares and reduce the ownership share of existing holders.
- Orphan drug designation:
- An FDA status for drugs treating rare diseases that can bring development incentives.
- Breakthrough therapy designation:
- An FDA status for drugs showing substantial improvement over existing treatments, intended to speed development and review.
FAQ
How much did Contineum Therapeutics lose in the first nine months of 2026?
The filing reports a net loss of $48.3 million for the nine months ended September 30, 2026, compared with $44.8 million a year earlier.
Did Contineum raise money by selling stock?
Yes, the filing shows $19.4 million in net proceeds from issuing common stock through an at-the-market offering in the period.
What regulatory risk does Contineum flag in the filing?
The filing says FDA staffing cuts and government shutdowns could slow reviews, responses and approvals of its drug candidates.
Historical context for CTNM
Across the 25 sessions after earlier CTNM headlines, the stock closed higher 14 times and lower 11 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CTNM | SPY |
|---|---|---|---|
| Nov 4, 2026 | Contineum Therapeutics Reports Third-Quarter 2026 Financial Results | +1.0% | +1.7% |
| Oct 30, 2026 | Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference | +0.6% | -1.8% |
| Oct 13, 2026 | Contineum Therapeutics downgraded by Robert W. Baird with a new price target | -1.7% | -0.0% |
| Sep 15, 2026 | Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder | -6.7% | -0.5% |
| Aug 26, 2026 | Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference | -0.2% | +0.0% |
| Jul 31, 2026 | Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones | -1.7% | +0.7% |
Keep researching CTNM
- CTNM financial statementsRevenue, profit, cash flow and balance sheet from Contineum Therapeutics Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- CTNM insider tradesEvery buy and sale reported by Contineum Therapeutics Inc. officers, directors and large holders.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Follow CTNM and get a push notification the moment its next story breaks.